Last reviewed · How we verify
Zomiperac (ZOMEPIRAC)
Zomiperac works by inhibiting the enzyme Prostaglandin G/H synthase 2, which plays a key role in pain and inflammation.
Zomiperac, also known as ZOMEPIRAC, is a small molecule drug that targets Prostaglandin G/H synthase 2. It belongs to the zomepirac drug class and was originally developed by an unknown entity. Unfortunately, there is limited information available on its commercial status, approved indications, and pharmacokinetic properties. As a result, its current owner, FDA approval status, half-life, bioavailability, generic manufacturers, and off-patent status remain unknown. Further research is necessary to determine its clinical utility and safety profile.
At a glance
| Generic name | ZOMEPIRAC |
|---|---|
| Drug class | zomepirac |
| Target | Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1980 |
Mechanism of action
Imagine your body's pain and inflammation response like a fire. Prostaglandin G/H synthase 2 is like the fuel that keeps the fire burning. Zomiperac helps put out the fire by blocking the fuel supply, reducing pain and inflammation.
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zomiperac CI brief — competitive landscape report
- Zomiperac updates RSS · CI watch RSS